New combo aims to stop liver cancer from coming back

NCT ID NCT07352007

Not yet recruiting Disease control Sponsor: Lei ZHAO Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether giving the immunotherapy drug sintilimab along with targeted radiation before surgery can lower the risk of liver cancer returning. About 110 patients with resectable liver cancer will be randomly assigned to receive the combination therapy before surgery or surgery alone. Both groups may also receive sintilimab after surgery for up to a year. The main goal is to see how many patients remain cancer-free after three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab (an immunotherapy drug) and stereotactic body radiotherapy (focused radiation)
What this could lead to: If successful, this approach could reduce the chance of liver cancer returning after surgery, potentially improving long-term survival.
What could go wrong: This is a mid-stage trial with only 110 participants, so results may not apply to all patients. The combination therapy may cause side effects like immune reactions or radiation damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

Contacts and locations

Locations

ShandongShandong Cancer Hospital and Institute

Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.